Search in this site

Grenoble Excellence in neurodegeneration Grenoble Excellence in neurodegeneration

Home > About GREEN > Management

See the complete sitemap

CV coordinator Frédéric Saudou

Current positions:

2014: Director of the Grenoble Institute of Neurosciences (GIN) (app. 250 persons) INSERM U836, University Grenoble Alpes, 38000 Grenoble, France

2014: Full Medicine Professor, Hospital Practitioner, Grenoble University Hospital

2014: Group leader GIN


1993: Ph.D., Louis Pasteur University, Strasbourg, France.
2001: Habilitation à Diriger les Recherches – Université Paris XI.


1990-1993:  MSc & PhD Student, R Hen lab, IGBMC, Strasbourg
1994-1996:  Postdoctoral fellow, JL Mandel Lab, IGBMC, Strasbourg (Dir P Chambon)
1996-1999:  Postdoctoral fellow, ME Greenberg lab, Harvard Med. School Boston
1994-2014:  Inserm Scientist Research director (DR1)
1999-2014:  Group Leader, Institut Curie
2004-2008:  Clinical research contract - Interface Clinique Inserm/AP-HP
2010-2014:  Head of Department Institut Curie/CNRS UMR3306/INSERM U1005


1999:  ATIP from CNRS (Young Investigator award from CNRS).
2002:  EMBO Young Investigator Program.
2004:  Jean Hamburger Prize of Medicine and Medical Research from la Ville de Paris
2011:  Rachel Azjen & Léon Iagolnitzer prize from the Fondation pour la Recherche Médicale.
2013:  Elected Batsheva de Rothschild Fellow for the Advancement of Science in Israel.
2014:  Richard Lounsbery prize from the French and US national academies of Science
2014:  Fondation Bettencourt Schueller Coups d’Elan award for French research.


Total of 71 publications referenced in PubMed with 52 peer-reviewed research articles, total of 7710 citations WO self citations– Average citation per item: 106 - H Index 37 (ISI Web of Sci). 8 Top 10% and 2 Top 1% over 20 peer-reviewed articles in the last 5 years.

5 selected publications

  • El-Daher MT, Hangen E, Bruyère J, Poizat G, Al-Ramahi I, Pardo R, NiBourg N, Souquere S, Mayet C, Pierron G, Lévêque-Fort S, Botas J, Humbert S and Saudou F (2015) Huntingtin proteolysis causes toxicity through dynamin 1 dysregulation EMBO J. 34 , 2255-71.
  • Zala D, … and Saudou F (2013) Vesicular glycolysis provides on-board energy for axonal transport. Cell. 152, 479-91. See highlights in Nat Rev Neurosci, 2013, 14, 156-157;News & Views in Nature, 2013, 495,178-180. (Top 1% ESI, F1000 25*)
  • Keryer G, … and Saudou F. (2011) Ciliogenesis is Regulated by the Huntingtin-HAP1- PCM1 Pathway and is Altered in Huntington Disease. J. Clin Invest.,121, 4372-4382.(Top 10% ESI).
  • Borrell-Pagès M., … Saudou F*. and Humbert S*. (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington’s disease through HSJ1b and transglutaminase J. Clin. Invest. 116, 1410-1424. *Co-corresponding authors.
  • Gauthier LR, … and Saudou F (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell, 118, 127- 138. (Top 1%, F1000 6*)

Updated on April 27, 2017

Associés renforcés
Associés simples